Back to search

Article

Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis

2022-08-26

Abstract excerpt

Objective: Currently, there is no data available on SARS-CoV-2 vaccine responses in pediatric-onset multiple sclerosis (POMS) and little is known about the course of SARS-CoV-2 infection in this age group. We therefore investigated humoral immune responses after Covid-19 vaccination and/or infection in POMS.<br><br>Methods: We retrospectively analyzed seroconversion rates and SARS-CoV-2 specific antibody levels in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cbbc44e7-da04-5bfd-831d-f1f86d1e175c
DOI
10.2139/ssrn.4193527
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple SclerosisDOI 10.2139/ssrn.4193527
Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patientsSemantic proximity
Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20 treated patients with multiple sclerosis after three or four COVID-19 vaccinationsSemantic proximity
Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapySemantic proximity
Effect of SARS-CoV-2 mRNA Vaccination in MS Patients Treated With Disease Modifying TherapiesSemantic proximity
Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune mediated inflammatory diseasesSemantic proximity
Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccinesSemantic proximity
Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patientsSemantic proximity
Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapySemantic proximity
Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273Semantic proximity
Longitudinal follow-up of SARS-CoV-2 vaccine- induced antibody responses in patients with multiple sclerosis treated with anti-CD20 therapySemantic proximity
Impaired Immunogenicity to COVID-19 Vaccines in Autoimmune Systemic Diseases - High Prevalence of Non-Response in Different Patients’ SubgroupsSemantic proximity
Impact of mass vaccination on SARS-CoV-2 infections among the total multiple sclerosis population receiving immunomodulatory disease-modifying therapies in EnglandSemantic proximity
Select a neighboring publication to make it the new centre.